Company profile for Soligenix

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Soligenix has specialized knowledge in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise. We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need. Soligenix has a number of Public Health programs, funded entirely by government grants and contra...
Soligenix has specialized knowledge in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise. We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need. Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
29 Emmons Drive Suite B-10 Princeton, NJ 08540
Telephone
Telephone
609-538-8200
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/05/3200703/0/en/Soligenix-Inc-NASDAQ-SNGX-Advancing-Rare-Disease-Therapies-Positioned-at-Pivotal-Crossroad.html

GLOBENEWSWIRE
05 Dec 2025

https://www.globenewswire.com/news-release/2025/12/04/3199778/0/en/Breakthrough-Therapies-Advance-as-Rare-Disease-Burden-Intensifies-Across-Aging-Populations.html

GLOBENEWSWIRE
04 Dec 2025

https://www.globenewswire.com/news-release/2025/12/03/3198880/0/en/Soligenix-Inc-NASDAQ-SNGX-Innovative-Platform-Provides-Novel-Treatment-for-Underserved-CTCL-Space.html

GLOBENEWSWIRE
03 Dec 2025

https://www.prnewswire.com/news-releases/soligenix-achieves-enrollment-milestone-for-planned-interim-analysis-in-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cutaneous-t-cell-lymphoma-302619926.html

PR NEWSWIRE
19 Nov 2025

https://www.prnewswire.com/news-releases/soligenix-announces-recent-accomplishments-and-third-quarter-2025-financial-results-302608194.html

PR NEWSWIRE
07 Nov 2025

https://www.prnewswire.com/news-releases/soligenix-updates-united-states-medical-advisory-board-for-cutaneous-t-cell-lymphoma-302582841.html

PR NEWSWIRE
14 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty